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Abstract
There is considerable interest in designing therapeutic studies of individuals at risk of Alzheimer disease (AD) to prevent the
onset of symptoms. Cortical b-amyloid plaques, the first stage of AD pathology, can be detected in vivo using positron
emission tomography (PET), and several studies have shown that ,1/3 of healthy elderly have significant b-amyloid
deposition. Here we assessed whether asymptomatic amyloid-PET-positive controls have increased rates of brain atrophy,
which could be harnessed as an outcome measure for AD prevention trials. We assessed 66 control subjects
(age = 73.567.3 yrs; MMSE= 2961.3) from the Australian Imaging Biomarkers & Lifestyle study who had a baseline
Pittsburgh Compound B (PiB) PET scan and two 3T MRI scans ,18-months apart. We calculated PET standard uptake value
ratios (SUVR), and classified individuals as amyloid-positive/negative. Baseline and 18-month MRI scans were registered, and
brain, hippocampal, and ventricular volumes and annualized volume changes calculated. Increasing baseline PiB-PET
measures of b-amyloid load correlated with hippocampal atrophy rate independent of age (p = 0.014). Twenty-two (1/3)
were PiB-positive (SUVR.1.40), the remaining 44 PiB-negative (SUVR#1.31). Compared to PiB-negatives, PiB-positive
individuals were older (76.867.5 vs. 71.767.5, p,0.05) and more were APOE4 positive (63.6% vs. 19.2%, p,0.01) but there
were no differences in baseline brain, ventricle or hippocampal volumes, either with or without correction for total
intracranial volume, once age and gender were accounted for. The PiB-positive group had greater total hippocampal loss
(0.0660.08 vs. 0.0260.05 ml/yr, p = 0.02), independent of age and gender, with non-significantly higher rates of whole brain
(7.169.4 vs. 4.765.5 ml/yr) and ventricular (2.063.0 vs. 1.161.0 ml/yr) change. Based on the observed effect size, recruiting
384 (95%CI 195–1080) amyloid-positive subjects/arm will provide 80% power to detect 25% absolute slowing of
hippocampal atrophy rate in an 18-month treatment trial. We conclude that hippocampal atrophy may be a feasible
outcome measure for secondary prevention studies in asymptomatic amyloidosis.
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Introduction
Despite intensive efforts, pharmacological strategies aimed at
disrupting the underlying pathology of Alzheimer’s disease (AD)
have thus far failed to translate into therapies for patients. One
explanation is that trials are being carried out too late in the
disease, and there is therefore considerable interest in identifying
and treating individuals as early as possible, with the aim of
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slowing or ideally preventing the development of cognitive
symptoms [1]. The development of biomarkers has made early
AD detection realistic: amyloid pathology can be quantified using
positron emission tomography (PET) [2,3]; Ab1-42 and tau can be
measured in cerebrospinal fluid (CSF) [4]; and rates of cerebral
atrophy can be quantified from serial MRI [5]. Numerous
biomarker studies have produced evidence that the AD patholog-
ical cascade starts many years prior to symptoms [6], paving the
way both for pre-symptomatic diagnosis of AD [7], and studies
aimed at preventing or delaying the onset of symptoms - secondary
prevention [1,8]. Recent CSF [9] and amyloid PET [10–13]
studies have shown that around a third of cognitively normal
individuals in their 70 s have significant amyloid deposition.
Whilst it is not yet known whether all individuals with
‘‘asymptomatic amyloidosis’’ will develop AD if they live long
enough, on a group level some [14], if not all [15] studies have
shown that these individuals have worse cognition, increased
cognitive decline [16,17], with some early evidence for a higher
risk of subsequent conversion to MCI or AD [16,18]. Major
therapeutic studies targeting elderly individuals with asymptomatic
amyloidosis are currently planned [19]. Here, we aimed to assess
whether using amyloid PET as an inclusion criteria, and atrophy
measured from serial MRI as an outcome measure, might be a
feasible means of helping to determine disease modifying effects in
AD secondary prevention studies.
Materials and Methods
Subjects
We used data from the Australian Imaging Biomarkers and
Lifestyle (AIBL) study. We included subjects designated as healthy
controls at baseline who had a Pittsburgh Compound B (PiB) 11C
PET scan and two 3T MRI volumetric scans ,18 months apart.
Details of the AIBL methodology have previously been reported
[20]. In brief healthy controls $60 years old were recruited from
the community, with ,50% having subjective memory complaints
and ,50% being APOE4 carriers. All subjects underwent
standardised clinical and neuropsychological examinations, in-
cluding the mini-mental state examination (MMSE) and clinical
dementia rating (CDR) scale, and underwent APOE genotyping.
Subjects were questioned to determine the presence/absence of
subjective cognitive impairment (SCI). Austin Health Human
Research Ethics Committee approved the study and subjects
provided written informed consent.
Image Acquisition
PiB-PET scans were acquired using an Allegro PET camera
(Phillips Medical Systems, The Netherlands). A transmission scan
was performed for attenuation correction. Participants received
370 MBq 11C-PiB over 1 minute, and a 20-minute acquisition (66
5-minute frames) in 3D-mode was performed beginning 50
minutes after injection. PET images were reconstructed using a
3D RAMLA algorithm [10]. Summed images from the 50 to 70
minute time-frame were used in this study. Sagittal T1-weighted
MRI brain scans were acquired at baseline and ,18 months using
a 3D magnetization prepared rapid gradient echo sequence on a
Siemens Trio Tim 3T scanner, with 161 mm in-plane resolution;
1.2 mm slice thickness; repetition time/echo time/inversion
time= 2,300 ms/2.98 ms/900 ms; flip angle 9u; field-of-view
2406256; and 160 slices.
Image Analysis
MRI volumes and atrophy rates. Images were corrected
for intensity inhomogeneity using the N3 algorithm [21].
Following 9-degrees-of-freedom registration of the follow-up to
baseline scans and differential bias correction [22], whole brain
and hippocampal segmentations were produced at each time-point
using BrainMAPS [23] and HippoMAPS [24] respectively. In line
with our practice for clinical trials, each segmented scan
underwent a visual quality control process, with minimal manual
editing where necessary. Ventricular volumes were delineated
semi-automatically using the MIDAS software package [25].
Volume change over time (millilitres) was obtained using the
boundary shift integral (BSI). Volume change was measured for
ventricles (VBSI) [26], hippocampus (HBSI) [24] and whole brain
(KN-BSI) [27]. Baseline total intracranial volume (TIV) was
estimated using the FreeSurfer [28] image analysis suite v4.5.0,
which employs the Buckner method [29].
Amyloid PET processing. Subsequent to the processing
described above, NiftySeg [30] was used to fractionate each MR
voxel into grey matter(GM), white matter and CSF tissue classes,
and to segment the cerebellum. Each MR scan was then
parcellated into regions of interest using the label fusion procedure
MultiSTEPS [31] with the Hammers 30-subject atlas [32]. To
achieve the best label propagation possible, atlases were non-
rigidly registered using NiftyReg [33], first to the group-wise
average image, and subsequently to each individual image. PET
images were rigidly registered to their corresponding MRI using a
block matching approach [34], and the MRI segmentations re-
sliced into PET space using trilinear interpolation. Mean PiB
uptake values in cerebellar GM (voxels containing $95% GM)
were used to normalise cerebral uptake, producing Standardized
Uptake Value Ratios (SUVRs). Neocortical masks were created by
combining a subset (frontal, temporal, parietal and occipital lobes
plus insula and cingulate cortex) of the parcellations with the GM
segmentations, discarding voxels with fractional volume below 5%.
The robust weighted mean SUVR under this mask was calculated
using the GM fractional volumes as weights and excluding the
highest and lowest 5% SUVR values.
Statistical Analyses
We used a hierarchical cluster analysis based on Ward’s linkage
[35] (using the ‘‘cluster wardslinkage’’ command in Stata) to
dichotomise the cohort on the basis of SUVR. Those with higher
SUVRs were designated PiB-positive, the remainder PiB-negative.
Standard linear regression models were fitted to explore the
association between SUVR, baseline brain volumes, atrophy rates
and age. Baseline characteristics, cross-sectional brain volume and
annualised atrophy rates were compared between PiB-positive/
negative groups using two-sample t-tests allowing for unequal
variances, Wilcoxon rank-sum tests, and Fisher’s exact test.
Further regression models were fitted which allowed for a shift
in mean atrophy rate and change in slope at the predefined SUVR
cut-off. Data from PiB-positives were used to estimate sample sizes
to provide 80% power, 5% type-1 error, to detect 25% absolute
reduction in whole brain, ventricular and hippocampal change
over 18-months, and to detect 25% absolute reduction as a
proportion of PiB-positive, PiB-negative group difference. Bias-
corrected and accelerated 95% bootstrap (100,000 samples)
confidence intervals were found for sample size estimates. Analyses
were performed in Stata12 (Stata Corp, TX).
Results
Baseline Characteristics and Rates of Change
Data from 67 individuals were available. Visual inspection of
the MRI scans revealed the development of a possible tumour in
one individual, who was excluded. Demographic and imaging data
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for the remaining 66 are shown in Table 1. Mean6SD age was
73.567.3 years, MMSE 29.061.3, and 35% were APOE4 positive.
Thirteen individuals (19.6%) had SCI; there was a trend for these
individuals to have higher MMSE scores than the remainder
(29.561.0 vs. 28.961.3, p= 0.06). Annualized rates of change for
the whole group were 5.567.0 ml/yr for brain loss, 1.461.9 ml/
yr for ventricular expansion and 0.03160.06 ml/yr for total
(left+right) hippocampal atrophy.
Correlating Baseline Amyloid Deposition with Baseline
Brain Volumes and Rates of Change
There was no significant relationship between baseline SUVR
and brain (p = 0.12, R2= 0.02) or ventricular volume (p = 0.34,
R2= 0.00), but a significant relationship between (greater) SUVR
and (smaller) baseline brain/TIV ratio (p = 0.007, R2= 0.09), and
hippocampal volume both with (p = 0.011, R2= 0.08) and without
(p = 0.008, R2= 0.09) correction for TIV. Increasing baseline
SUVR was associated with higher rate of volume loss in the right
hippocampus (p,0.001), left hippocampus (p,0.001), and total
hippocampi (p,0.001, R2= 0.19) (Figure 1A). There was border-
line evidence for an association between baseline SUVR and
ventricular expansion rate (p = 0.07, R2= 0.04), and a non-
significant but positive association with whole brain atrophy
(p = 0.2, R2 = 0.01).
Across the whole cohort, both increasing baseline SUVR
(p= 0.003, R2= 0.12) and increasing hippocampal atrophy rate
(p = 0.006, R2= 0.10) were associated with increasing age, but we
found no statistically significant relationship between age and
brain or ventricular rates of change. In a multivariable regression
analysis, the relationship between baseline SUVR and baseline
hippocampal volume or brain/TIV ratio was not significant when
accounting for age and gender. However the relationship between
SUVR and hippocampal atrophy rate remained statistically
significant after adjusting for age and ApoE4 positivity, with no
evidence that this was influenced by either gender or years of
education.
Comparing PiB-positive and PiB-negative Groups
The cluster analysis separated subjects into two distinct groups,
one with SUVR#1.31 (PiB-negative, n= 44), the other with
SUVR.1.40 (PiB-positive, n = 22). Baseline SUVR correlated
with increasing age in the PiB-negative (p,0.05, R2= 0.07), but
not PiB-positive group (p = 0.4), although the difference in slopes
was not statistically significant (p = 0.074). There was a significant
association between total hippocampal volume loss and baseline
SUVR (independent of age) in the PiB-positive (p = 0.02, R2= 0.2)
but not PiB-negative group (p= 0.7) (Figure 1B,C), although the
difference in slopes failed to reach significance (p = 0.21).
Table 2 shows the baseline and longitudinal results for the PiB-
positive and PiB-negative groups. PiB-positive individuals were
older (76.865.7 vs. 71.867.4, p,0.01), and more likely to be
APOE4 positive (63.6% vs. 19.2%, p,0.01) but there were no
significant differences in baseline ventricular, or hippocampal
volumes (with or without correction for TIV) or TIV, either
including or excluding SCI individuals. The PIB-positive group
had smaller brain/TIV volumes than the PIB-negative group
(70.763.7 vs. 72.863.3%, p= 0.03), but this was no longer
significant when age and gender were accounted for. The PiB-
positive group had greater combined hippocampal loss (0.0660.07
vs. 0.0260.05 ml/yr, p = 0.02) independent of baseline age or
gender. The PiB-positive group also had non-significantly higher
rates of whole brain (7.169.3 vs. 4.765.4 ml/yr, p = 0.3) and
ventricular (2.063.0 vs. 1.160.9 ml/yr; p = 0.2) change. Given
the relatively small sample size we repeated the analysis of the
hippocampal atrophy rates using non-parametric statistics (Wil-
coxon rank-sum test), confirming significantly higher rates of
atrophy in the PiB-positive group (median[IQR]= 0.04[0.09] vs.
0.02[0.06] ml/yr, p = 0.04]. At an SUVR cut-off of 1.5– a value
used in other studies [10,13] –18/69 subjects were amyloid-
positive; mean hippocampal atrophy rates were hardly changed
and still significantly higher than in the amyloid-negative group
using both parametric (0.0660.08 vs. 0.0260.06 ml/yr, p= 0.04)
and non-parametric (0.04[0.1] vs. 0.02[0.06]ml/yr, p = 0.02)
approaches, with consistently higher, but non-significant rates of
whole brain atrophy and ventricular expansion.
Excluding Individuals with Subjective Cognitive
Impairment or CDR = 0.5
Excluding individuals with SCI (n= 13) did not materially alter
results: there was still a significant relationship between SUVR and
hippocampal atrophy rate (p,0.001, R2= 0.2) with weak evidence
for associations with ventricular expansion (p= 0.08) and whole
brain atrophy rate (p = 0.1); and significantly higher rates of
hippocampal atrophy in the PiB-positive group (p= 0.04). Whilst
all subjects’ clinical diagnoses were assessed by a clinical review
panel, to ensure that the four subjects with CDR=0.5 were not
influencing the results we re-ran our analyses excluding these
individuals. Across the group as a whole there was still a significant
relationship between SUVR and hippocampal atrophy rate
(p = 0.02); the relationship with ventricular expansion was now
significant (p = 0.04), and with whole brain atrophy rate borderline
significant (p = 0.07). Comparing the PiB-positive and PiB negative
Table 1. Baseline demographics, APOE genotypes, Brain
Volumes, and 1-Year Rates of Atrophy for all individuals
included in the study.
Characteristic Mean ± SD, or % 95% CI
Age, yr 73.567.3 71.7–75.3
Gender, % male 45.5% –
APOE e4, % positive 34.8% –
MMSE 29.061.3 28.7–29.3
CDR-Sum of boxes 0 (n = 64); 0.5 (n = 4) –
Subjective Cognitive Complaints n = 13 (19.7%) –
MRI Scan Interval, days 558695 534.4–581.3
Baseline brain volume, ml 10886105 1062–1113
Baseline TIV 15126159 1473–1550
Baseline ventricular volume, ml 35.4620.2 30.4–40.1
Baseline left hippocampal volume, ml 2.7160.37 2.62–2.80
Baseline right hippocampal volume, ml 2.6060.37 2.51–2.69
Baseline total hippocampal volume, ml 5.3160.72 5.11–5.48
Inter-scan interval (days) 558695 534–581
Whole brain atrophy rate, ml/yr 5.4667.0 3.94–7.24
Ventricular expansion rate, ml/yr 1.3961.90 0.95–1.86
Left hippocampus loss, ml/yr 0.01660.037 0.007–0.025
Right hippocampus loss, ml/yr 0.01560.030 0.008–0.022
Total hippocampal atrophy rate, ml/yr 0.03160.061 0.016–0.046
NC= normal control; SD = standard deviation; CI = confidence interval;
MMSE =Mini Mental State Examination; CDR-SB =Clinical Dementia Rating –
Sum of Boxes.
doi:10.1371/journal.pone.0058816.t001
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Figure 1. Plots of baseline SUVR vs. annualized hippocampal change. (A) The relationships and regression slope for the group as a whole;
(B) APOE4 individuals shown in closed circles; (C) subjective cognitive impairment individuals shown in closed circles. SUVR values between 1.31 and
1.40 separate the groups: a reference line at SUVR= 1.35 is shown for illustration.
doi:10.1371/journal.pone.0058816.g001
Table 2. Baseline demographics, APOE genotypes, Brain Volumes, and 1-Year Rates of Atrophy in PiB-positive and PiB-negative
individuals.
Characteristic NC-low, SUVR #1.31, n=44 NC-high, SUVR .1.4, n=22 p
Mean ± SD 95% CI Mean ± SD 95% CI
Age, yr 71.867.4 69.6–74.1 76.865.7 74.3–79.4 0.004
Gender, % male 47% – 50% – 0.61
APOE e4, % positive 20.5% – 63.6% – 0.001
MMSE 29.161.2 28.8–29.5 28.861.3 28.2–29.4 0.35
CDR-Sum of boxes = 0.5 (n,%) 2 (4.5%) – 2 (9.1%) – 0.60
Scan Interval, days 558.86102.1 527.8–589.8 555.9682.4 519.4–592.5 0.90
Baseline brain volume, ml 10986105 1066–1130 10666103 1021–1112 0.25
Baseline TIV 15126162 1463–1561 15116157 1441–1580 0.98
Baseline ventricular volume, ml 35.5620.6 29.2–41.7 35.2619.9 26.4–44.1 0.96
Baseline left hippocampal volume, ml 2.7560.33 2.65–2.85 2.6460.43 2.45–2.83 0.28
Baseline right hippocampal volume, ml 2.6360.33 2.53–2.73 2.5460.43 2.35–2.73 0.40
Baseline total hippocampal volume, ml 5.3860.65 5.18–5.57 5.1760.85 4.80–5.55 0.33
Whole brain atrophy rate, ml/yr 4.765.4 3.0–6.3 7.169.4 2.9–11.2 0.28
Ventricular expansion rate, ml/yr 1.0760.88 0.81–1.34 2.0163.01 0.68–3.35 0.16
Left Hippocampus loss, ml/yr 0.00860.031 20.001–0.018 0.03260.043 0.013–0.051 0.03
Right hippocampus loss, ml/yr 0.00860.023 0.001–0.016 0.02960.036 0.013–0.045 0.03
Total Hippocampal atrophy rate, ml/yr 0.01660.047 0.004–0.031 0.06060.075 0.027–0.093 0.02
NC= normal control; SD = standard deviation; CI = confidence interval; MMSE =Mini Mental State Examination; CDR-SB = Clinical Dementia Rating – Sum of Boxes.
doi:10.1371/journal.pone.0058816.t002
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groups, again there were significantly higher rates of hippocampal
atrophy in the former (p = 0.04).
Sample Size Calculations
Recruiting amyloid-positive subjects to power a one-year
treatment trial to detect 25% absolute slowing of cerebral atrophy
rates (equivalent to ,35% slowing if the maximum effect was to
reduce atrophy rate to the mean loss in the PiB-negative group)
requires 442 (95% CI 180,1650) subjects/arm using whole brain
atrophy, 542 (180,1649) using ventricular expansion and 384
(195,1080) using hippocampal atrophy rates.
Discussion
In this study we demonstrate a significant relationship between
hippocampal atrophy rates and amyloid load in cognitively normal
individuals, and show that this is independent of increasing age. In
the absence of significant demographic or baseline cross-sectional
volumetric differences, and independent of including/excluding
individuals with SCI, PiB-positive controls (,1/3 of the cohort)
had significantly higher rates of hippocampal atrophy. Finally, we
provide sample size estimates for therapeutic trials seeking to assess
disease-modification effects using rates of hippocampal (and brain)
atrophy as outcome measures in asymptomatic amyloid-positive
individuals who may be at risk of AD.
As a group, the rates of volume change over time are very
similar to those we have previously derived using similar
techniques in a larger (n = 199, mean age ,76 yrs) cohort of
ADNI controls [26]. Here rates of whole brain atrophy were
5.666.9 ml/yr, and in ADNI 6.366.1 ml/yr; total hippocampal
atrophy 0.0460.1 vs. 0.0560.1 ml/yr.; and ventricular expansion
1.461.9 vs. 1.461.6 ml/yr. Despite preferential recruitment of
SCI individuals in AIBL, these results suggest that the two groups
are comparable; and with the caveats that rates of APOE4
positivity are high (,29%, ADNI; ,35%, AIBL), and that
individuals recruited to observational studies may not represent
the population in general, these results may be reasonably
generalizable to populations who might be recruited for preven-
tion trials.
We found a relationship between baseline amyloid load and
rates of atrophy, significantly so for hippocampal volume loss. This
result – based on volumetric measures of change using well
validated techniques – confirm those previously shown in AIBL
using voxel-wise analyses [36]; and again, despite differences in
inter-scan interval and recruitment strategy are very similar to the
relationships we have previously reported in ADNI controls,
dichotomised using CSF Ab1-42 [37]. Whilst previous work has
shown a relationship between age and baseline SUVR, [10] we
found that the relationship between brain atrophy rate and SUVR
for the group as a whole was independent of age, gender or
baseline MMSE, providing further evidence for a relationship
between amyloid deposition and neurodegeneration, as has been
previously demonstrated in very early AD [38]. Whilst there was a
significant relationship between increasing amyloid load and both
smaller hippocampal volumes and brain/TIV ratios across the
group as a whole, these relationships were no longer present once
age and gender were accounted for. Whilst numbers are small,
taken together these findings are consistent with the formulation
that amyloid deposition leads to excess hippocampal atrophy rates
which, over time, result in differences in mean hippocampal
volumes at a group level.
In keeping with previous amyloid PET studies, we dichotomised
the group into amyloid-positive/negative on the basis of SUVR,
determining a cut-off consistent with a value of 1.4 defined in
previous AIBL studies [36,39]. At this level, ,1/3 of this
cognitively normal cohort were amyloid-positive, in keeping with
previous PET [10,36,39] and CSF [9,40] studies. As in prior
studies, PiB-positive individuals were older and more likely to be
APOE4 positive than PiB-negatives [10]. Whilst hippocampal
volumes were slightly smaller in the PiB-positive group, there were
no significant differences in baseline hippocampal volumes
between the groups, either including or excluding subjects with
SCI, or correcting for TIV. These findings, similar to those we
reported when comparing normal controls dichotomised on the
basis of CSF Ab1-42, [36] are at odds with some studies reporting
lower temporal lobe volumes in PiB-positive individuals [11,13],
and others including Chetelat et al who found increased temporal
lobe (including hippocampal) volume in PiB positive, SCI-negative
AIBL controls [39]. It is unclear whether these discrepancies relate
to methodological differences, relatively small sample sizes, or the
more limited and specific regions we assessed. Importantly, only
3/22 of the amyloid-positive group had total hippocampal
volumes outside the lower limit of the 95% reference range for
the amyloid-negative group, suggesting that the vast majority
would fulfil proposed criteria for isolated asymptomatic Ab-
amyloidosis [7]. Whilst we found no differences in ventricular
volumes between the groups, the PIB positive group had
significantly (3%, p= 0.03) smaller brain volume as a proportion
of TIV. However, this difference was no longer significant
(p = 0.075) once age and gender were accounted for.
Comparing longitudinal rates of atrophy with the PiB-negative
group, PiB-positives had ,50% higher rates of brain atrophy,
,double the rate of ventricular expansion, and ,three-fold – and
significantly – higher rates of hippocampal atrophy. These
differences are remarkably similar to those we have previously
shown in ADNI control subjects [36], an independent sample
dichotomised using a different biomarker of amyloid deposition,
CSF Ab1-42 which is inversely correlated to PET amyloid load
[41] (Table 3). Importantly, dichotomising the groups at a slightly
higher SUVR of 1.5, as has been used in some AIBL [10,11,17]
and other studies [42] produced very similar results. These results
provide evidence for a fundamental difference between healthy,
amyloid-negative, aging where rates of atrophy in the mid-70 s are
,0.3–0.4%/year for brain and ,0.4–0.6%/yr for combined
hippocampi, and higher rates of loss in asymptomatic (CSF or PIB
positive) amyloidosis of ,0.7–0.9%/yr for brain and ,1.3–1.4%/
yr for hippocampi. It is notable that in asymptomatic amyloidosis,
rates are not only intermediate between ‘‘normality’’ and those
seen in mild cognitive impairment, but also show a dispropor-
tionate effect on the hippocampi relative to whole brain, in
keeping with the hypothesis that these individuals might be in the
earliest stages of AD [43].
We found a significant relationship between amyloid load and
hippocampal atrophy rate in the amyloid-positive but not amyloid-
negative group. Although, perhaps due to limited power,
differences between slopes did not reach significance, this is
consistent with the hypothesis that the relationship between
amyloid accumulation and atrophy differs between normal aging
and early AD; and that amyloid burden may need to reach a
critical level before excess neurodegeneration is triggered [6]. It is
noteworthy that individuals with SCI had rather higher MMSE
scores than the remainder of the group and, as shown in Figure 1
(C), were rather more likely to be PiB-negative than positive.
Whilst based on a relatively small sample size, these results provide
some preliminary data to suggest that for trials aiming to recruit
PiB-positive controls, there may be more to be gained through
enriching for APOE4 which is strongly, albeit not exclusively,
associated with PiB-positivity [44] (Figure 1 B), than through
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enrichment for SCI. However, as is evident from the Figure 1,
amyloid positivity is not exclusive to APOE4 individuals, and so
whilst preferentially recruiting APOE4 individuals is likely to
increase the numbers of amyloid-positive individuals detected, this
strategy comes with the risk of potentially reducing the general-
izability of any results to the wider population. Whilst numbers are
small and there was no evidence for differences in rate of
hippocampal atrophy between APOE4 carriers (n = 14,
0.06760.078 ml/yr) and non-carriers (n = 8, 0.04960.072 ml/
yr, p= 0.59) within the amyloid-positive group, potential differen-
tial effects of therapy based on APOE4 status as has been observed
in immunotherapy studies [45] may also influence recruitment
strategy.
For pre-symptomatic prevention clinical trials, these data
suggest that using hippocampal atrophy rate, ,380 PiB-positive
individuals would be required per arm of an 18-month placebo/
controlled study to detect 25% absolute slowing of brain atrophy
(i.e.,35% decline relative to ‘‘healthy’’, amyloid-negative, normal
aging). It is worth noting that these numbers refer to the numbers
needed to complete the study with adequate imaging at baseline
and follow-up, and in practice trial design must allow for drop-outs
and poor scans. We report sample sizes over 18-months, the
approximate inter-scan interval in this study. It is likely that
within-subject SDs (and hence sample sizes) would be slightly
higher if measured over one year, and slightly lower over longer
intervals [46]; nonetheless, these figures are not dissimilar to those
we have previously estimated based on one-year ADNI data [37].
Whilst the wide confidence intervals should be noted, sample sizes
of this order are within the scale of proposed prevention studies,
such as the A4 study which proposes to recruit ,1000 amyloid-
positive individuals [19]. Prevention studies are likely to be run
over relatively long periods and to use conversion status or
cognitive scores as principal outcome measures. In this context,
rates of hippocampal or brain atrophy may be particularly
valuable in providing interim assessments of disease modification
[47].
There are a number of caveats of this study, particularly with
reference to applications in therapeutic studies. The number of
individuals included is modest, only two scanning time-points were
used for analysis, and our estimates are based on a 25% absolute
slowing of atrophy: accordingly any sample size estimates need to
be viewed with caution particularly given the wide confidence
limits (195–1080) we report. Similarly, the relatively small number
of individuals in the study may also explain some of the differences
in sample size estimates between this study and our prior report
[37]. Some of the hippocampal volumes in this study appear to
show increases over time (i.e. negative rates of atrophy). This may
reflect real physiological changes (e.g. an individual’s level of
hydration), or image artefacts (e.g. motion), noise or voxel drift in
the MR scans, which may result in apparent negative changes
when the underlying ground-truth atrophy rate is close to zero
[48]. Finally, whilst the rationale for using atrophy as an outcome
is that a disease-modifying drug would slow rates of change, prior
amyloid vaccination studies in AD [49] and emerging results from
some recently completed trials [50] in AD have shown unexpected
excess volume loss in patients on active treatment, demonstrating
that there may be an unexpected dissociation between biomarker
changes and clinical outcomes. It may however be that the effects
of treatment on those already in the clinical stages of AD might
differ from those at an early, pre-symptomatic, stage of AD
pathology, which is the target group for our study; and it is likely
that biomarker changes may provide invaluable mechanistic
information even in failed studies. For these reasons, it is vitally
important to have an understanding of the relationship between
atrophy and amyloid load in asymptomatic amyloidosis. Further
larger studies with longer follow-up are required to explore these
issues in more detail, but our results suggest that there does appear
already to be a ‘‘signal’’ of excess atrophy in the asymptomatic
amyloidosis group, which could be exploited for the purposes of
clinical trials.
In conclusion we provide further evidence that asymptomatic
amyloidosis is not a benign state, but is associated with increased
neurodegeneration. Longitudinal follow-up is required to deter-
mine whether the combination of amyloidosis and increased rates
of cerebral atrophy can predict accurately whether an individual
will develop AD, and if so over what time frame. These results
suggest however that hippocampal and brain atrophy, measured
using validated, quantitative techniques, may be a useful outcome
measure, potentially providing additional information in trials
Table 3. Baseline demographics, APOE genotype, neuropsychometry, SUVR, brain volumes and annualised rates of atrophy in
amyloid positive and negative normal controls from this study compared to ADNI amyloid positive/negative individuals defined on
the basis of CSF Ab1-42.
Characteristic Amyloid ‘‘negative’’ Mean ± SD Amyloid ‘‘positive’’ Mean ± SD
AIBL (n =44) ADNI (n =65) AIBL (n=22) ADNI (n =40)
Age, yr 71.867.4 74.965.1 76.865.7 76.365.1
Gender, % male 47% 51% 50% 55%
APOE e4, % positive 20.5% 10.8% 63.6% 47.5%
MMSE 29.161.2 29.061.1 28.861.3 29.260.9
Baseline brain volume, ml 10986105 10546103 10666103 10776105
Baseline ventricular volume, ml 35.5620.6 35.8620.9 35.2619.9 39.4616.2
Baseline total hippocampal volume, ml 5.3860.65 5.2660.70 5.1760.85 5.1760.62
Whole brain atrophy rate, ml/yr 4.765.4 4.465.3 7.169.4 9.366.9
Ventricular expansion rate, ml/yr 1.0760.88 0.9561.14 2.0163.01 2.0461.93
Hippocampal atrophy rate, ml/yr 0.0260.05 0.0360.09 0.0660.08 0.0760.10
NC= normal control; SD = standard deviation; CI = confidence interval; MMSE =Mini Mental State Examination.
doi:10.1371/journal.pone.0058816.t003
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designed to detect disease-modification in asymptomatic individ-
uals with amyloidosis.
Acknowledgments
Data used in the preparation of this article was obtained from the
Australian Imaging Biomarkers and Lifestyle flagship study of ageing
(AIBL) which was made available at the ADNI database (www.loni.ucla.
edu/ADNI). AIBL researchers are listed at www.aibl.csiro.au. We thank
the AIBL Study Group for providing this data. We also thank all the AIBL
participants and their carers for their valuable contribution to Alzheimer’s
research.
Author Contributions
Performed expert segmentations: TY KEM. Contributed methods and
software used for automatic segmentation/registration/atrophy quantifi-
cation: MJC MM KKL. Contributed critically to data interpretation: JB
NCF SO. Performed data acquisition: VLV CCR. Contributed critically to
revision of manuscript: NCF SO VLV KKLMJCMMKEM JB TY CCR.
Conceived and designed the experiments: KAA JMS JB SO NCF.
Performed the experiments: KAA MM MJC KKL. Analyzed the data:
KAA JMS. Contributed reagents/materials/analysis tools: VLV CCR.
Wrote the paper: KAA JMS.
References
1. Reiman EM, Langbaum JBS, Fleisher AS, Caselli RJ, Chen K, et al. (2011)
Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of
presymptomatic treatments. J Alzheimers Dis 26 Suppl 3: 321–329.
doi:10.3233/JAD-2011-0059.
2. Herholz K, Ebmeier K (2011) Clinical amyloid imaging in Alzheimer’s disease.
Lancet Neurol 10: 667–670. doi:10.1016/S1474-4422(11)70123-5.
3. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. (2004) Imaging
brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol
55: 306–319. doi:10.1002/ana.20009.
4. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, et al. (2009)
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive
impairment. JAMA 302: 385–393. doi:10.1001/jama.2009.1064.
5. Fox NC, Schott JM (2004) Imaging cerebral atrophy: normal ageing to
Alzheimer’s disease. Lancet 363: 392–394. doi:10.1016/S0140-6736(04)15441-
X.
6. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al. (2010)
Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological
cascade. Lancet Neurol 9: 119–128. doi:10.1016/S1474-4422(09)70299-6.
7. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. (2011) Toward
defining the preclinical stages of Alzheimer’s disease: recommendations from the
National Institute on Aging-Alzheimer’s Association workgroups on diagnostic
guidelines for Alzheimer’s disease. Alzheimer’s & dementia : the journal of the
Alzheimer’s Association. Vol. 7. 280–292. doi:10.1016/j.jalz.2011.03.003.
8. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, et al. (2011)
Autosomal-dominant Alzheimer’s disease: a review and proposal for the
prevention of Alzheimer’s disease. Alzheimers Res Ther 3: 1. doi:10.1186/
alzrt59.
9. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, et al.
(2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroim-
aging initiative subjects. Ann Neurol 65: 403–413. doi:10.1002/ana.21610.
10. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, et al. (2010) Amyloid
imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL)
study of aging. Neurobiol Aging 31: 1275–1283. doi:10.1016/j.neurobiola-
ging.2010.04.007.
11. Bourgeat P, Che´telat G, Villemagne VL, Fripp J, Raniga P, et al. (2010) Beta-
amyloid burden in the temporal neocortex is related to hippocampal atrophy in
elderly subjects without dementia. Neurology 74: 121–127. doi:10.1212/
WNL.0b013e3181c918b5.
12. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, et al. (2007) Beta-amyloid
imaging and memory in non-demented individuals: evidence for preclinical
Alzheimer’s disease. Brain 130: 2837–2844. doi:10.1093/brain/awm238.
13. Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, et al. (2008) 11C PiB
and structural MRI provide complementary information in imaging of
Alzheimer’s disease and amnestic mild cognitive impairment. Brain 131: 665–
680. doi:10.1093/brain/awm336.
14. Rodrigue KM, Kennedy KM, Devous MD, Rieck JR, Hebrank AC, et al. (2012)
b-Amyloid burden in healthy aging: regional distribution and cognitive
consequences. Neurology 78: 387–395. doi:10.1212/WNL.0b013e318245d295.
15. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, et al (2008)
Frequent amyloid deposition without significant cognitive impairment among
the elderly. Arch Neurol 65(11): 1509–17. doi: 10.1001/arch-
neur.65.11.1509.16.
16. Morris JC, Roe CM, Grant EA, Head D, Storandt M, et al. (2009) Pittsburgh
compound B imaging and prediction of progression from cognitive normality to
symptomatic Alzheimer disease. Arch Neurol 66: 1469–1475. doi:10.1001/
archneurol.2009.269.
17. Villemagne VL, Pike KE, Che´telat G, Ellis KA, Mulligan RS, et al. (2011)
Longitudinal assessment of Ab and cognition in aging and Alzheimer disease.
Ann Neurol 69: 181–192. doi:10.1002/ana.22248.
18. Knopman DS, Jack CR, Wiste HJ, Weigand SD, Vemuri P, et al. (2012) Short-
term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.
Neurology 78: 1576–1582. doi:10.1212/WNL.0b013e3182563bbe.
19. Strobel G (2011) Anti-Amyloid Treatment in Asymptomatic AD Trial
Alzheimer Research Forum. Available at: http://www.alzforum.org/new/
detail.asp?id = 3014. Accessed 1 June 2012.
20. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, et al. (2009) The Australian
Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and
baseline characteristics of 1112 individuals recruited for a longitudinal study of
Alzheimer’s disease. Int Psychogeriatr 21: 672–687. doi:10.1017/
S1041610209009405.
21. Boyes RG, Gunter JL, Frost C, Janke AL, Yeatman T, et al. (2008) Intensity
non-uniformity correction using N3 on 3-T scanners with multichannel phased
array coi ls . Neuroimage 39: 1752–1762. doi :10.1016/j.neuro-
image.2007.10.026.
22. Lewis EB, Fox NC (2004) Correction of differential intensity inhomogeneity in
longitudinal MR images. Neuroimage 23: 75–83. doi:10.1016/j.neuro-
image.2004.04.030.
23. Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, et al. (2011) Brain
MAPS: an automated, accurate and robust brain extraction technique using a
template library. Neuroimage 55: 1091–1108. doi:10.1016/j.neuro-
image.2010.12.067.
24. Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, et al. (2010)
Automated cross-sectional and longitudinal hippocampal volume measurement
in mild cognitive impairment and Alzheimer’s disease. Neuroimage 51: 1345–
1359. doi:10.1016/j.neuroimage.2010.03.018.
25. Evans MC, Barnes J, Nielsen C, Kim LG, Clegg SL, et al. (2010) Volume
changes in Alzheimer’s disease and mild cognitive impairment: cognitive
associations. Eur Radiol 20: 674–682. doi:10.1007/s00330-009-1581-5.
26. Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, et al. (2010) Reduced
sample sizes for atrophy outcomes in Alzheimer’s disease trials: baseline
adjustment. Neurobiol Aging 31: 1452–62, 1462.e1-2. doi:10.1016/j.neurobio-
laging.2010.04.011.
27. Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR, et al. (2010) Robust
atrophy rate measurement in Alzheimer’s disease using multi-site serial MRI:
tissue-specific intensity normalization and parameter selection. Neuroimage 50:
516–523. doi:10.1016/j.neuroimage.2009.12.059.
28. Athinoula A. Martinos Center at the Massachusetts General Hospital, Harvard
Medical School. FreeSurfer. Available to download at: http://www.surfer.nmr.
mgh.harvard.edu/.
29. Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, et al. (2004) A unified
approach for morphometric and functional data analysis in young, old, and
demented adults using automated atlas-based head size normalization: reliability
and validation against manual measurement of total intracranial volume.
NeuroImage 23: 724–738. doi:10.1016/j.neuroimage.2004.06.018.
30. Cardoso MJ, Clarkson MJ, Ridgway GR, Modat M, Fox NC, et al. (2011)
LoAd: a locally adaptive cortical segmentation algorithm. Neuroimage 56:
1386–1397. doi:10.1016/j.neuroimage.2011.02.013.
31. Cardoso MJ, Leung KK, Modat M, Keihaninejad S, Cash D, et al. (2013)
STEPS: Similarity and Truth Estimation for Propagated Segmentations and its
application to hippocampal segmentation and brain parcellation. Medical Image
Analysis (in press).
32. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, et al. (2003) Three-
dimensional maximum probability atlas of the human brain, with particular
reference to the temporal lobe. Hum Brain Mapp 19: 224–247. doi:10.1002/
hbm.10123.
33. Modat M, Ridgway GR, Taylor ZA, Lehmann M, Barnes J, et al. (2010) Fast
free-form deformation using graphics processing units. Comput Methods
Programs Biomed 98: 278–284. doi:10.1016/j.cmpb.2009.09.002.
34. Ourselin S, Roche A, Subsol G, Pennec X, Ayache N (2001) Reconstructing a
3D structure from serial histological sections. Image and Vision Computing. Vol.
19. 25–31.
35. WARD J (1963) Hierarchical Grouping to Optimize an Objective Function.
J Am Stat Assoc 58: 236–&.
36. Che´telat G, Villemagne VL, Villain N, Jones G, Ellis KA, et al. (2012)
Accelerated cortical atrophy in cognitively normal elderly with high b-amyloid
deposition. Neurology 78: 477–484. doi:10.1212/WNL.0b013e318246d67a.
37. Schott JM, Bartlett JW, Fox NC, Barnes J, Alzheimer’s Disease Neuroimaging
Initiative Investigators (2010) Increased brain atrophy rates in cognitively
normal older adults with low cerebrospinal fluid Ab1–42. Ann Neurol 68: 825–
834. doi:10.1002/ana.22315.
Hippocampal Atrophy Rates in PiB Positive Controls
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e58816
38. Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW, et al. (2011) Spatial
patterns of brain amyloid-beta burden and atrophy rate associations in mild
cognitive impairment. Brain 134: 1077–1088. doi:10.1093/brain/awr044.
39. Che´telat G, Villemagne VL, Pike KE, Baron J-C, Bourgeat P, et al. (2010)
Larger temporal volume in elderly with high versus low beta-amyloid deposition.
Brain 133: 3349–3358. doi:10.1093/brain/awq187.
40. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, et
al. (2010) Diagnosis-independent Alzheimer disease biomarker signature in
cognitively normal elderly people. Arch Neurol 67: 949–956. doi:10.1001/
archneurol.2010.179.
41. Fagan AM, Mintun MA, Mach RH, Lee S-Y, Dence CS, et al. (2006) Inverse
relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42
in humans. Ann Neurol 59: 512–519. doi:10.1002/ana.20730.
42. Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, et al. (2010) Brain
beta-amyloid measures and magnetic resonance imaging atrophy both predict
time-to-progression from mild cognitive impairment to Alzheimer’s disease.
Brain 133: 3336–3348. doi:10.1093/brain/awq277.
43. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, et al.
(1996) Presymptomatic hippocampal atrophy in Alzheimer’s disease. A
longitudinal MRI study. Brain 119 (Pt 6): 2001–2007.
44. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, et al. (2010) APOE
predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal
aging. Ann Neurol 67: 122–131. doi:10.1002/ana.21843.
45. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, et al. (2009) A phase 2
multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer
disease. Neurology 73: 2061–2070. doi:10.1212/WNL.0b013e3181c67808.
46. Schott JM, Frost C, Whitwell JL, Macmanus DG, Boyes RG, et al. (2006)
Combining short interval MRI in Alzheimer’s disease: Implications for
therapeutic trials. J Neurol 253: 1147–1153. doi:10.1007/s00415-006-0173-4.
47. Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, et al. (2011) Prevention
trials in Alzheimer’s disease: an EU-US task force report. Prog Neurobiol 95:
594–600. doi:10.1016/j.pneurobio.2011.08.014.
48. Barnes J, Foster J, Boyes RG, Pepple T, Moore EK, et al. (2008) A comparison
of methods for the automated calculation of volumes and atrophy rates in the
hippocampus. NeuroImage 40: 1655–1671. doi:10.1016/j.neuro-
image.2008.01.012.
49. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, et al. (2005) Effects of
Abeta immunization (AN1792) on MRI measures of cerebral volume in
Alzhe imer d i sea se . Neuro logy 64 : 1563–1572 . do i :10 .1212/
01.WNL.0000159743.08996.99.
50. Fox NC (2012) Bapineuzumab Phase 3 trials in mild to moderate Alzheimer’s
disease dementia in apolipoproteinE e4 carriers (Study 302) and non-carriers
(Study 301): CSF and Volumetric MRI Biomarkers. Clinical Trials in
Alzheimer’s Disease. Available at: http://www.ctad.fr/07-download/
Congres2012/PressRelease/Final-Fox-CTAD-Presentation-10-29-12.pdf. Ac-
cessed: 27 Nov 2012.
Hippocampal Atrophy Rates in PiB Positive Controls
PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e58816
